Bronchiectasis: a new look at an old adversary
- Amy McLean
- Aust Prescr 2008;31:77-9
- 1 June 2008
- DOI: 10.18773/austprescr.2008.044
The management of bronchiectasis is finally advancing and patients have new options in terms of diagnostics, antibiotic therapy and physiotherapy. The principles of management have not changed, but with some simple interventions patients can experience improved quality of life and health outcomes. Many treatments developed for cystic fibrosis are now being applied to the management of bronchiectasis due to other causes.
For many healthcare professionals, the term 'bronchiectasis' conjures up a bygone era of cold damp houses and coughing children. Today there is a revived interest in this condition among respiratory physicians and after many stagnant years we are able to offer something new.
The management of cystic fibrosis has rapidly improved over the past 20 years with vastly improved life expectancies. Research has flourished, and many treatments developed for the management of cystic fibrosis-related bronchiectasis are already being used in non-cystic fibrosis bronchiectasis sufferers in the clinical setting. Compared to other respiratory disorders such as asthma, evidence for the safety and efficacy of treatments used in bronchiectasis is scarce.
There are a number of commonly asked questions regarding bronchiectasis in general practice.
The advent of high resolution CT scans means there is a new gold standard for diagnosis.1We are able to assess the anatomy and severity of patients with known disease more accurately as well as diagnosing new patients. High resolution CT chest scanning should be performed at diagnosis and as determined by clinical progress. Chest X-rays are most useful in evaluating complications such as pneumonia.
Functional monitoring with spirometry (and lung volumes where available) is very useful and should be performed both during exacerbations and in stable periods. The frequency of testing will depend on the deterioration and exacerbation rate for the individual patient.
Sputum cultures should be done when the patient is stable and, ideally, not taking antibiotics. This information can then be used to guide the management of their next exacerbation. Patients on long-term macrolide antibiotics can still be managed along the same lines, as these drugs (in the low doses used) have little effect on actual pathogens isolated and on antibiotic susceptibility profiles.
If no sputum culture is available for a particular patient, collect a sample then treat for the more common pathogens, for example Haemophilus influenzae, with drugs such as amoxycillin/clavulanic acid or roxithromycin. If the patient fails to respond, consider treating empirically for pseudomonas pending the results of sputum culture.
We know a lot more about this pathogen than we used to. We are now aware that it forms three-dimensional structures, referred to as biofilms, which adhere to the respiratory epithelium and resist antibiotic penetration. Patients colonised with pseudomonas have a worse prognosis and more rapid decline in lung function than those who are not.2 During an exacerbation, patients with pseudomonas should be treated aggressively with antipseudomonal antibiotics. A suitable oral antibiotic would be ciprofloxacin for at least 14 days. Patients who develop resistance to ciprofloxacin should be considered for combination treatment with ciprofloxacin and nebulised aminoglycoside (for example tobramycin). This is usually best administered in consultation with a hospital respiratory outpatient unit. Inpatients are usually treated with ticarcillin/clavulanic acid combined with an inhaled or intravenous aminoglycoside. For chronic colonisation, patients should probably have a trial of long-term macrolide antibiotics.3
Physiotherapy is still considered an essential part of bronchiectasis management and research has consistently shown it to be of benefit. For example, patients with cystic fibrosis had a faster decline in lung function when they were non-compliant with chest physiotherapy. Options for physiotherapy are broader than they used to be. Easy to use hand-held devices such as positive expiratory pressure or flutter devices in addition to active-cycle breathing techniques are an option for many patients. Postural drainage still has a place for heavy sputum producers. Refer your patients to a local respiratory physiotherapist for advice on this important management tool.
The cautious answer to this question is, 'We don't know'. There has been a lot of research in this area in cystic fibrosis. Several large clinical trials of macrolide antibiotics in cystic fibrosis have shown improvements in various clinical outcomes including sputum production and quality of life.3 A lot of bench research has shown that macrolide antibiotics have anti-inflammatory effects and this may be the mechanism by which they help in cystic fibrosis. Many respiratory colleagues now give patients a trial of a low-dose regular macrolide, for example azithromycin 250 mg daily or clarithromycin 125 mg twice a day, for a few months and assess for improvements in sputum production and exacerbation rates. A large randomised controlled trial of this strategy has not yet been done.
Bronchiectasis is an inflammatory condition in which the ongoing damage of the airways is due to the inflammatory response to pathogens. Inhaled corticosteroids reduce this inflammatory damage. Several randomised controlled trials have shown a benefit of inhaled corticosteroids in patients with bronchiectasis, with the main improvements being reduced sputum production and exacerbations.4
Drugs to assist sputum clearance are seeing a revival with research into using two osmotic agents - nebulised hypertonic saline and inhaled mannitol. Both of these agents have been shown to assist sputum clearance predominantly by increasing hydration of the sputum and improving the viscosity. Hypertonic saline has been shown to reduce exacerbation rates in a large cystic fibrosis trial.5 In non-randomised studies, mannitol improved airway clearance and quality of life in patients with non-cystic fibrosis bronchiectasis. A large randomised controlled trial has just been completed. Neither treatment is available commercially at the time of writing but hypertonic saline is available through public hospital outpatient clinics, and mannitol should be available as a metered-dose inhaler over the next few years.
Editorial note (October 2008)
A formulation of hypertonic saline has been listed on the Australian Register of Therapeutic Goods and is now available for purchase from some hospital pharmacies.
All patients with chronic lung disease and dyspnoea warrant some form of pulmonary rehabilitation to prevent the inevitable deconditioning that occurs and exacerbates the dyspnoea. There has not been much research for patients with bronchiectasis, but one study has clearly demonstrated benefit.6
The important long-term sequelae in bronchiectasis are respiratory failure, cor pulmonale, nocturnal hypoventilation, poor nutrition, osteoporosis and haemoptysis.
Respiratory failure can be hypoxic or hypercapnic or both. Hypoxic patients benefit from home oxygen and this can be prescribed by a respiratory physician. Hypercapnic patients may benefit from treatment with non-invasive ventilation, that is bi-level positive airway pressure or variable positive airway pressure.
Cor pulmonale will present with the development of right heart failure symptoms (ankle swelling, often the first thing noticed by the patient) and this should prompt investigation with echocardiography to measure right heart parameters as well as consideration of fluid restriction and diuretics.
Patients with nocturnal hypoventilation will complain of poor sleep, morning headaches and excessive daytime sleepiness. They should be referred to a respiratory/sleep physician for an assessment.
Nutritional deficiency is common in this condition due to the chronic inflammatory state, breathlessness and poor appetite. Patients who are struggling should be weighed each appointment and encouraged to try calorific supplements and see a dietitian.
Osteoporosis is common because patients may have received a lot of prednisone in the past and have nutritional deficiency. Also, a high proportion of patients are postmenopausal women. Broken ribs and vertebral crush fractures can be a problem in patients with lung disease who have become unable to complete physiotherapy and suffer worsening respiratory failure using adequate analgesia. It is best to prevent this with calcium supplementation and bisphosphonates. These patients should probably have an annual bone mineral density scan.
Haemoptysis is dangerous and can occur at any stage of the disease. It requires prompt assessment in a hospital environment. These patients can bleed profusely due to abnormal vasculature, and asphyxiation can develop quickly because of poor gas exchange.
Depending on your local resources, the development of any of these conditions should prompt referral to a specialist centre with multidisciplinary experience in the management of chronic lung disease.
Patients with bronchiectasis should be considered 'at risk' for serious sequelae from pneumococccal and influenzal illness. They should be given the pneumococcal vaccine and an annual influenza vaccine.
Patients with bronchiectasis experience a lot of morbidity. The management requires attention to a diverse range of concerns, but each intervention is simple and generally easily available. A holistic management strategy will improve health outcomes and quality of life.
Respiratory and Sleep Physician, Royal Prince Alfred Hospital, Sydney